SENIOR BIOSTATISTICIAN
OPPORTUNITY TO MAKE A DIFFERENCE
Early diagnosis of cancer can make a huge difference to survival rates. A new and exciting opportunity exists for a senior biostatistician to make a real difference by joining Oncimmune, an innovative small company that develops diagnostic tests in oncology. Your statistical expertise will be critical for us to improve the sensitivity, specificity and robustness of our assays and analyse our clinical trials. In this challenging and varied role, you will collaborate effectively in a team environment, playing a central role within our team consisting of scientists, clinicians and a data manager.
The successful candidate will have excellent communication, presentation and report writing skills. A willingness to learn about oncology and the biomarkers that are important to early diagnosis and the ability to discuss trial designs and effectively communicate your statistical findings to non-statisticians are essential criteria. You will have a higher degree in statistics and experience of applied statistics including generalised linear models. Experience of analysing and reporting of large clinical studies using SPSS (or other statistical packages), case-control studies, ELISA assays, calibration, stability issues and working in GLP or GCP environments would be an advantage.
We offer a competitive salary and are conveniently located for using the facilities at the University of Nottingham. Please apply by sending your CV and a covering letter stating your current salary to Emma Jenkins, Oncimmune Ltd, Clinical Sciences Building, City Hospital, Hucknall Road, Nottingham, NG5 1PB or by e-mail to [log in to unmask] with reference "Senior biostatistician: Allstat". Closing date is 21st August with interviews anticipated on 3rd September.
This message has been checked for viruses but the contents of an attachment
may still contain software viruses, which could damage your computer system:
you are advised to perform your own checks. Email communications with the
University of Nottingham may be monitored as permitted by UK legislation.
|